My question to the MND webinar.
Riluzole blocks release of glutamate through reduced synapse formation and subsequent electrical activity.
It has a low grade autophagic component in Beclin 1 and LC3AII.
Monepantel disrupts P13K via the mTOR pathway.
Both P13K and Beclin 1 are responsible for considered autophagy in the human body.
If one was to companion Riluzole and Monepantel together the synergy of P13K and Beclin 1 it may possibly recruit to the mitochondria and golgi apparatus to form an isolated membrane in phagophore through recycling the endosome.
Ref : Oncotarget 2016 Zhan et al
Ref : Impaired autophagy in motor neurones: A final common mechanism of injury and death. Gonzales et al 2018.
Ann: First Patient Dosed in MND Phase 1/2 Trial, page-123
-
- There are more pages in this discussion • 49 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
19.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $86.55M | |||
| Open | High | Low | Value | Volume |
| 19.5¢ | 19.5¢ | 18.5¢ | $330.4K | 1.741M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4071 | 19.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 19.5¢ | 24580 | 3 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| PAA (ASX) Chart |